Disclosures for "Safety, Tolerability, and Efficacy of Bexicaserin in a Cohort of Participants With Developmental and Epileptic Encephalopathies: Interim Results of a Phase 1b/2a PACIFIC Study Open-Label Extension"
-
Dr. Le has received personal compensation for serving as an employee of Lundbeck Pharmaceuticals. Dr. Le has stock in Longboard Pharmaceuticals.
-
Dr. Smith has nothing to disclose.
-
Miss Weberg has nothing to disclose.
-
Ms. Polega has nothing to disclose.